The risk factor they hope you skip is the word "acceptable." When a vendor says it slashed inference cost through quantization, the unstated clause is "with acceptable accuracy loss" — and "acceptable" is doing enormous work. The patents make the trade-off explicit. Intel's published application US20250238664A1, "Adaptation of quantization of neural network models during inference" (published 2025-07-24), is about adjusting precision dynamically — strong evidence that fixed low precision is not free, or you would not need to adapt it.
Baidu's granted patent US12008467B2, "Asymmetric quantization for compression and for acceleration of inference for neural networks" (issued 2024-06-11), points at the same tension from another angle: asymmetric schemes exist because naive quantization distorts the numbers unevenly and costs accuracy. The existence of clever methods is itself the disclosure — if cheap precision were lossless, the IP would be trivial and nobody would file.
Buried in the mechanism is the early warning. Quantization saves money because lower-precision arithmetic uses less memory bandwidth and fewer transistor cycles. But a model's quality can degrade as precision drops, and the degradation is not uniform across tasks. Methods that adapt precision during inference, or that quantize asymmetrically, are engineering admissions that the savings come with a quality cost someone has to manage.
Disclosed, but quietly: no public filing breaks out "savings from quantization" as a line item, and none discloses the accuracy hit either. The trade-off lives in the patent literature and the engineering, not in the income statement. So when a cost claim arrives with no accuracy caveat, the caveat has not disappeared — it has just been left out of the slide.
Compare the framing year over year, as this column does with risk factors. The pattern in the patent record is consistent: more sophisticated quantization methods keep appearing, which means the easy savings were taken long ago and the remaining gains require managing accuracy risk ever more carefully. That trajectory is the opposite of "free lunch."
The disciplined read for a markets audience: treat "we lowered inference cost" as a claim with two terms, not one. The cost reduction may be real; the accuracy cost is real too, and it is the part vendors under-disclose. The quantization patents are the receipts showing both halves of the trade exist.